Mesothelioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
In line with the screen results, primary mesothelioma (BAP1+/-) overexpressing BAP1 C91A (catalytically dead mutant) were more resistant to RNR inhibition, while BAP1 knockdown in the BAP1-proficient cell lines rescued the cells from their vulnerability to RNR depletion.
|
31619462 |
2020 |
Mesothelioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Surface components of MM of the pleura showed concordant loss as the invasive tumor suggesting a potential role for BAP1 loss for recognizing so-called early mesothelioma.
|
30640754 |
2020 |
Mesothelioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Combinations of staining using cyclin D1 >50% plus BAP1 or MTAP loss in epithelial mesotheliomas produced about a 10% increase in sensitivity.
|
31685964 |
2020 |
Mesothelioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
While the BAP1-mutated subgroup is similar to diffuse malignant pleural mesotheliomas, the TRAF7-mutated subgroup overlaps genetically with adenomatoid tumors and well-differentiated papillary mesotheliomas, in which recurrent TRAF7 mutations have been described.
|
31371807 |
2020 |
Mesothelioma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Immunocytochemical studies on PF cell blocks allow: (a) to distinguish mesothelioma from reactive mesothelial proliferations (e.g. loss of BAP1 nuclear expression, complemented by the demonstration of p16 deletion using fluorescence in situ hybridization, indicate mesothelioma); (b) to separate mesothelioma from adenocarcinoma (e.g. calretinin, CK 5/6, WT-1 and D2-40 are markers of mesothelioma, whereas CEA, EPCAM, TTF-1, napsin A, and claudin 4 are markers of carcinoma); and (c) to reveal tumor origin in pleural metastases of an unknown primary site (e.g.
|
30354850 |
2019 |
Mesothelioma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Cytologic identification of mesothelioma is particularly challenging, but testing for BAP1 nuclear expression (immunocytochemistry) and p16 deletion (fluorescence in situ hybridization) has greatly improved our diagnostic capabilities.
|
31082996 |
2019 |
Mesothelioma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Retrospective response analysis of BAP1 expression to predict the clinical activity of systemic cytotoxic chemotherapy in mesothelioma.
|
30642545 |
2019 |
Mesothelioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
We studied 49 cases of mesothelioma (17 epithelioid mesothelioma, 22 biphasic mesothelioma, and 10 sarcomatoid mesothelioma) and 23 benign mesothelial proliferations using a 5-hmC single immunohistochemical stain, CAM5.2/5-hmC double immunohistochemical stain, and BAP1 immunohistochemistry.
|
30315275 |
2019 |
Mesothelioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Here, we report a novel pathogenic BAP1 germline variant in a family with a history of BIMTs, cutaneous melanomas, and mesotheliomas.
|
31706282 |
2019 |
Mesothelioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The deubiquitinating enzyme BAP1 is mutated in a hereditary cancer syndrome with a high risk of mesothelioma and melanocytic tumors.
|
30156010 |
2019 |
Mesothelioma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry demonstrated intact BAP1 expression in all cases of well-differentiated papillary mesothelioma, indicating that this is a reliable marker for distinguishing well-differentiated papillary mesothelioma from malignant mesotheliomas that frequently display loss of expression.
|
30171198 |
2019 |
Mesothelioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The prevalence of pathogenic germline BAP1 mutations in patients with mesothelioma was 4.4% (95% confidence interval 1.1-11.1).
|
31323388 |
2019 |
Mesothelioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Loss of BAP1 as a candidate predictive biomarker for immunotherapy of mesothelioma.
|
30914057 |
2019 |
Mesothelioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
BAP1 loss was detected in 61/88 (69%) tissues and in 20/30 (67%) cytology samples from mesothelioma with a specificity of 100% for both sampling methods.
|
31165505 |
2019 |
Mesothelioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
Loss of BAP1 function is implicated in the oncogenesis of several types of cancers including uveal, mucosal and some cutaneous melanomas in humans, as well as in mesothelioma.
|
30060843 |
2018 |
Mesothelioma
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Finally, the protein levels of ASXL2, BAP1 and UBE2E enzymes are highly correlated in mesothelioma tumors suggesting the importance of this signaling axis for tumor suppression.
|
30349006 |
2018 |
Mesothelioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
BAP1 was lost in 46 (87%) mesotheliomas compared with 4 (2%) of 205 other cancers (P < .001), resulting in sensitivity and specificity of 87% and 98%, respectively.
|
29802871 |
2018 |
Mesothelioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
None of the reported biomarkers showed adequate diagnostic accuracy, except for <i>p16</i> [evaluated by fluorescent in situ hybridization (FISH)] and BAP1 (evaluated by IHC), both biomarkers are recommended by the International Mesothelioma Interest Group guidelines for histological and cytological diagnosis.
|
29507804 |
2018 |
Mesothelioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Sensitivity to asbestos is increased in patients with mesothelioma and pathogenic germline variants in BAP1 or other DNA repair genes.
|
30338612 |
2018 |
Mesothelioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
These findings lead us to hypothesize that the mesothelioma occurred in the setting of germline a BAP1 mutation.This was confirmed by genetic testing.
|
30001711 |
2018 |
Mesothelioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A high proportion of mesothelioma harbor mutations in the BRCA1-associated protein 1 (BAP1) gene.
|
29206890 |
2018 |
Mesothelioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
A small number of mesotheliomas (probably in the order of 1%) are caused by germline mutations/deletions of BRCA1-associated protein-1 ( BAP1) in kindreds that also develop a variety of other cancers.
|
29480760 |
2018 |
Mesothelioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A combination of MTAP and BAP1 immunohistochemistry in pleural effusion cytology for the diagnosis of mesothelioma.
|
29053210 |
2018 |
Mesothelioma
|
0.600 |
Biomarker
|
disease |
BEFREE |
A Subset of Mesotheliomas With Improved Survival Occurring in Carriers of BAP1 and Other Germline Mutations.
|
30376426 |
2018 |
Mesothelioma
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Germline mutations in BAP1 are responsible for a rare cancer predisposition syndrome that includes predisposition to mesothelioma.
|
28687356 |
2017 |